Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERYTHROMYCIN-RESISTANT STAPH FOUND IN 74.4% OF CULTURES

This article was originally published in The Tan Sheet

Executive Summary

ERYTHROMYCIN-RESISTANT STAPH FOUND IN 74.4% OF CULTURES from treated patients in a study of 2% topical erythromycin conducted by Procter & Gamble to support a potential OTC switch for the treatment of acne. Presenting the data at a joint meeting of FDA's Dermatologic & Ophthalmic Drugs, Anti-Infective Drugs and Nonprescription Drugs Advisory Committees on Nov. 16, P&G said that 28.4% cultures from untreated patients showed bacterial strains resistant to erythromycin. A total of 830 strains of Staphylococci were isolated from treated and untreated patients, of which 50.4% were determined to be erythromycin-resistant.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel